Joana Carvalho, PhD, managing science editor —

One of the most promising therapeutic avenues for Parkinson’s disease is the use of stem cells to replace dopamine-producing neurons, the loss of which is a hallmark of the disease. This is the focus of a special issue on Parkinson’s disease published in the journal Stem Cells and…

A new long-lasting formulation of exendin-4, called PT302, reduced neurodegeneration in a rat model of Parkinson’s disease, according to new data from a preclinical study by Peptron. The study, “Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat…

Researchers have analyzed the three-dimensional toxic form of the protein alpha-synuclein, which is directly involved in Parkinson’s disease. The findings are now challenging previous knowledge investigators had of this disease. Parkinson’s disease is a progressive neurodegenrative disorder that belongs to the class of synucleopathies. In these type of diseases,…